Home › Lupus Nephritis › New York
Lupus Nephritis clinical trials in New York
16 studies for Lupus Nephritis are looking for participants at sites in New York.
Cities in New York
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Stony Brook Internists PC, East Setauket
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Oct 1, 2026 · NCT05268289Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
- Circuit Clinical, Orchard Park
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 28, 2026 · NCT06711887A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- New York Medical College, Hawthorne
- NorthWell, New Hyde Park
RecruitingPhase 2
Ages 16 to 70 · All sexes · Updated Sep 17, 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
- Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset
- Hospital for Special Surgery, New York: Division of Rheumatology, New York
- Columbia University Medical Center: Department of Medicine, Division of Rheumatology, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05201469The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
- Hospital for Special Surgery, New York
- Children's Hospital at Montefiore, New York
RecruitingPhase 2
Ages 8 to 20 · All sexes · Updated Sep 14, 2026 · NCT05538208A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, New York
- Research Site, Syracuse
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 10, 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Cohen Children's Medical Center of New York, Queens
RecruitingPhase 2
Ages 5 to 17 · All sexes · Updated Sep 3, 2026 · NCT05039619RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Rochester, Rochester
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Aug 26, 2026 · NCT06121297Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
- Icahn School of Medicine at Mount Sinai, New York
- State University of New York Upstate Medical Center (SUNY), Syracuse
RecruitingPhase 2
Ages 12 to 65 · All sexes · Updated Aug 24, 2026 · NCT07053800PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Buffalo Rheumatology and Medicine, PLLC, Orchard Park
RecruitingPhase 4
Ages 18 to 75 · All sexes · Updated Aug 3, 2026 · NCT07611214A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
- Nkarta Investigational Site, New York
- Nkarta Investigational Site, Stony Brook
- Nkarta Investigational Site, Syracuse
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 4, 2026 · NCT06557265A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Montefiore Medical Center, New York
RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978Lupus Landmark Study: A Prospective Registry and Biorepository
- The Feinstein Institutes for Medical Research, Manhasset
- Columbia University Medical Center, New York
- Northwell Health, New York
- and 1 more
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Apr 15, 2026 · NCT05934149Safety and Efficacy of ONT01 in Lupus
- Hospital for Special Surgery, New York
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Nov 20, 2025 · NCT07107659Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
- The Rogosin Institute, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 4, 2025 · NCT01802034From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.